 
 
  Page  1   
 
 
Using Aromatherapy for Comfort, Ease, and Stress for Adults Being 
Treated for Substance Use Disorder in North Central Appalachia: A 
Randomized Controlled Trial  
[STUDY_ID_REMOVED] 
December  27, 202 3 
 
   
 
      
 
 
 
  Page  2   
  
 
      
INVESTIGATOR INITIATED PROTOCOL  
AROMATHERAPY  & SUD  
[EMAIL_10999]  
WEST VIRGINIA UNIVERSITY  
       AROMATHERAPY & SUD STUDY PROTOCOL  
 
 
  Page  [ADDRESS_760015]  ............................................................................................................... 9 
Study Team  ......................................................................................................................... 11 
Research Summary  ...................................................................................................................... 11 
Updates to Study Protocol  ................................................................................................... 11 
Update: IRB amendment 09262022 (Appendix G)  ......................................................................... 11 
Update: IRB Amendment 08312022 (Appendix H)  ......................................................................... 11 
Update: From QIP Audit 10252022 (Appendix I)  ............................................................................ 11 
Study Population  ................................................................................................................................................ 12 
Study Design  ................................................................................................................................ 12 
Study Duration (7 days)  ................................................................................................................ 13 
Study Time Involved for Participants  ............................................................................................ 13 
Time involved in completing prescreening, informational session, & pre -surveys  ........................................... [ADDRESS_760016] -surveys  ......................................... 14 
Background & Significance  .................................................................................................. 15 
Prevalence Information ...................................................................................................................................... 15 
Significance to Nursing ....................................................................................................................................... 16 
Background  ........................................................................................................................................................ 16 
Objectives  ........................................................................................................................... 17 
Purpose:  ............................................................................................................................................................. 17 
 
 
  Page  4  Primary Objectives & Aims:  ................................................................................................................................ 17 
Study Design & Methodology  .............................................................................................. 17 
Risk ............................................................................................................................................. 17 
Benefits  ....................................................................................................................................... 18 
Statistical Analysis Plan  ....................................................................................................... 18 
Sample Size .................................................................................................................................. 18 
Data Safety Monitoring  ................................................................................................................ 19 
Safety Monitoring & Unanticipated Event Reporting  ..................................................................... 19 
Study Duration & Timeline  ................................................................................................... 20 
Informed Consent Process  .................................................................................................... 20 
Informed Consent Process  ............................................................................................................ 21 
Confidentiality & Privacy  .............................................................................................................. 21 
Other Considerations  ........................................................................................................... 21 
Supplies Available for Enrolling Participants (Kept in Locked Office):  .................................... 22 
*Surveys Used in this Study (See Appendix A)  ............................................................................... 22 
**Aroma Inhalers Used in this Study (See Appendix B)  .................................................................. 22 
Contents of Study Packets  ............................................................................................................ 22 
Prior to opening a Study Packet  .................................................................................................... 23 
a. Inclusion criteria  ....................................................................................................................................... 23 
b. Exclusion criteria  ....................................................................................................................................... 23 
 
 
  Page  5  3. IF PARTICIPANT IS INELIGIBLE,  .................................................................................................................. 23 
4. IF PARTICIPANT IS ELIGIBLE  ...................................................................................................................... 23 
Study Packet is Opened  ................................................................................................................ 23 
7. Consent form  ............................................................................................................................................ 24 
8. Pre-surveys for Comfort, Ease, and Stress ................................................................................................ 24 
Use of the Aethereo®Stick is reviewed (Appendix B for details about inhaler): .............................. [ADDRESS_760017] in Participant Packet:  .......................................................................... 26 
INTERVENTION:  ........................................................................................................................... 26 
CONTROL:  .................................................................................................................................... 26 
How Participants are Returning Study Materials:  .................................................................  [ADDRESS_760018]  ............................................................................................................................................. 27 
Frequently Asked Questions:  ................................................................................................ 28 
What if a Participant Loses Their Aroma Inhaler?  .......................................................................... 28 
What if a Participant has a Reaction? ............................................................................................ 28 
What if a Participant Wants to Withdraw from the Study?  ............................................................ [ADDRESS_760019] SURVEY  ............................................................................................................................... 40 
Appendix B  .......................................................................................................................... 42 
SAFETY DATA SHEET  ..................................................................................................................... 42 
MANUFACTURER SAFETY DATA SHEET  .......................................................................................... 43 
GAS CHROMATOGRAPHY/MASS SPECTROMETRY (GC/MS) ........................................................... [ADDRESS_760020] EXPI[INVESTIGATOR_578343]  .................................................................................................  48 
Appendix C  .......................................................................................................................... 49 
Cover Letter (Formatted per IRB)  .................................................................................................. 49 
Appendix D  .................................................................................................................................. 50 
Logbooks for Intervention & Control Groups  ................................................................................. 50 
Appendix E  .......................................................................................................................... 69 
Reminder Paper  ........................................................................................................................... 69 
Appendix F  .......................................................................................................................... 71 
Why is this research being done and what is involved?  .................................................................  [ADDRESS_760021] to participate and what are the risks involved?  .............................................................. [ADDRESS_760022] questions or concerns?  ......................................................................... 72 
Informed Consent for Research | Minimal Risk  ....................................................................... 0 
Introduction ..................................................................................................................................0  
Purpose  .........................................................................................................................................0  
Description of Procedures  ..............................................................................................................0  
Risks and Discomforts  ....................................................................................................................1  
Alternatives  ...................................................................................................................................2  
Benefits  .........................................................................................................................................2  
Financial Considerations  ................................................................................................................2  
Confidentiality  ...............................................................................................................................3  
HIPAA Authorization  ......................................................................................................................3  
Persons/Organizations Receiving the Information  ............................................................................................ [ADDRESS_760023] Persons  .............................................................................................................................5  
Signatures and Authorization .........................................................................................................6  
Participant Signature  ............................................................................................................................................ 6 
Consenting Individual Signature  .......................................................................................................................... 6 
Appendix G (IRB Update allowing Stages one, two, three, and peer recovery recruitment)  ..... 8 
Appendix H (IRB approval to recruit online complete consent online)  ................................... 10 
Appendix I (QIP Audit letter from IRB)  .................................................................................. 12 
 
 
  Page  8   
  
 
 
  Page  9  Study Protocol  
Title: Using aromatherapy for comfort, ease, and stress for adults being treated for substance 
use disorder in north central Appalachia: A randomized controlled trial  
 INSTITUTIONAL REVIEW BOARD APPROVAL NUMBER: __  [PHONE_11993]
___ 
CHESTNUT RIDGE APPROVAL FORM: _ on file 7/29/2022__  
 CLINICAL TRIAL NUMBER: __ [STUDY_ID_REMOVED]__  
 
Common Terms  List 
Enroller – person who works with potential study participants to complete prescreening and 
explain study. This will be Investigator Marian Reven or designee.  
 Participant – one who is willing and able to voluntarily participate in this study.  
 Aroma Inhaler – A small tube -shaped device about the size of a lipstick container. It contains a 
pure cotton wick. This wick is impregnated with pure essential oil. This is done at the manufacturer site. An Aethereo®Stick is used for this study. See appendix B for more information.  
 Aromatherapy – the use of aromas usually in the form of essential oils to impact a person’s 
feelings of health and wellbeing.  
 Bergamot essential oil – is a citrus essential oil extracted from the rind of the fruit Bergamot 
(Citrus bergamia). The aroma is described as sharp, fruity, powdery, and refreshing. Research 
shows that chemical constituents found in Bergamot (linalool and linalyl acetate) may impact nerve receptors to bring about anxiolytic effects.  
 Randomized Controlled Trial (RCT) – a type of study where participants are randomly assigned 
to either an intervention or a control group. In this way, the risk of bias is decreased. Packets are distributed in an exact order and the Enroller does not pi[INVESTIGATOR_578344].  
 Random Number Table (RNT) – used to minimize risk of bias in studies. A table of numbers 
generated in an unpredictable, haphazard sequence.   
Master Log Sheet (MLS) – Securely maintained Excel spreadsheet used to track assignment of 
participants to intervention or control groups. Also used to track those who are ineligible as 
determined by [CONTACT_578361] . 
 
 
  Page  10    
 
 
  Page  11  Study Team  
Principle -Investigator ( PI): Marian “Marnie” Reven, [EMAIL_11000]  or 304 -479-
4825  
 
Co-Investigator (CoI):  Amanda Newhouse, [EMAIL_11001]  or [ADDRESS_760024] Virginia University  
 
Research Summary  
Updates to Study Protocol  
Update: IRB amendment 09262022 (Appendix G)  
To allow Stages one, two, and three and peer recovery persons to participate.  
Update: IRB Amendment 08312022 (Appendix H)  
To recruit and consent participants online  
Update: From QIP Audit 10252022 (Appendix I)  
Annual Review  with approval received 7/29/2023  
8/23/[ADDRESS_760025] approval to proceed with recruitment when IRB approval is obtained.  
 
Update to consent process 8/2023 ( completed ) 
Communication with participants, begin using RedCap WVU for all surveys and emails. WVU 
phone and computer for all communication.  
 10/23/2023 Update: Will no longer include copy of consent in study packets mailed to participants. This will save on mailing costs. Participants can downlo ad and print or save to their 
devices. Approved 11/7/2023  
 11/21/23 Submitted amendment re: addition of Abigail Farris and Ella Jane Dailey CITI training certificates to the protocol  
 12/27/23 Amendment to add a population from Health Right , approved 2/5/2024  
 
 
 
  Page  12  Study Population  
Adults (>18 years) who are currently receiving treatment for SUD in the outpatient treatment 
program at West Virginia University Chestnut Ridge Center (WVUCRC) (n = 340 approx.).  
 
Inclusion criteria are patients diagnosed with SUD who have completed intensive acute phase 1 
treatment, and who desire to pursue continuous recovery phases (per facility protocol). All participants must be alert and oriented, provide written consent, and be able to read and write 
English.  
 Exclusion criteria are patients diagnosed with severe mental illness (who cannot consent to participate), have a medical history of asthma or other serious respi[INVESTIGATOR_3765], and known 
allergy to citrus.  There are no exclusion criteria for gender, race, and/or ethnicity.  
 
Anyone who meets inclusion criteria in the sample population is invited to participate. I am advertising throughout entire population of the study.  
 
Study Design  
The purpose of this study is to see if Bergamot, an aroma therapy essential oil, has any effect on comfort, ease, and stress. Participants will be asked to use a bergamot aroma inhaler, which is a small tube about the size of a lipstick container, at least  three times a day for one week. 
Comfort, ease, and stress will be measured with self -report survey at the beginning and at the 
end of the week. In addition, participants will be asked to complete a daily logbook to record use of the inhaler. The study las ts for one week (7 days). The aims of this study are to explore 
the effects of Bergamot essential oil on comfort, ease, and stress in adults in a SUD treatment program, and to evaluate the feasibility of this type of aroma therapy intervention.  
 
 
 
  Page  13  Study Duration  (7 days)  
 
Study Time Involved for Participants  
Time involved in completing prescreening, informational session, & pre -surveys  
 Step  What is 
happening  Who does what  Approximately 
how much time to 
expect  
1 Prescreening  6 question 
survey  Administered by 
[CONTACT_578362]  2-3 minutes  
2 Open packet & review 
contents  
Complete CONSENT  Looking at 
contents of 
packets  Enroller reviews 
consent & participant will either sign or 
decline  5-10 minutes  
2a Trying out aroma 
inhaler & giving directions for use  Participant 
opening their own aroma inhaler  Participant opens 
aroma inhaler. Enroller demonstrates 
correct use using 
their own inhaler  1-2 minutes  
2b Personalizing packet for 
each participant  Adding dates 
and organizing 
packet, going Enroller adds 
dates with 
participant 2-4 minutes  

 
 
  Page  14  over logbook 
together  involvement. 
Enroller explains 
follow up texts or emails that participant will 
begin receiving 
the next day.  
3 Complete 3 pre -surveys  69 questions (28 
GCQ, 20 Ease, 21 
DASS)  Participant does 
this and then they 
are excused  5-[ADDRESS_760026] -surveys  
 Step  What is 
happening  Who does what 
& extra details  Approximately 
how much time 
to expect  
[ADDRESS_760027] 3 days of the study. This reminder should not add 
any extra time 
to the study  21 minutes  
2 
Intervention  Filling out daily 
logbook x 7 days  Participant puts 
an X or check 
mark next to the 3 spaces to document use of aroma inhaler. Also, at the end of the participant’s day, Comfort is 
rated on a [ADDRESS_760028] for comments is available and participants may take their time to add comments about the day 
(this is 
discretionary)  7-10 minutes  
 
 
  Page  15  2 Control  Filling out daily 
logbook x 7 days  At the end of 
the 
participant’s day, Comfort is rated on a [ADDRESS_760029] for comments is available and 
participants 
may take their time to add comments about the day (this is 
discretionary)  Same as 
Intervention group  
[ADDRESS_760030] 
surveys/ logbook  Participant is 
completing the logbook for [ADDRESS_760031] 
aromatic survey. They are then sealing the envelop and mailing back to WVU CRC 
(preaddressed)  5-6 
   TOTALS  34-37 minutes  
 
Background & Significance  
Prevalence Information  
 
During 2017 –2019, the annual average prevalence of past -year substance use disorder  
in West Virginia was 13.4% (or 24,000), similar to both the regional average  
(15.1%) and the national average (14.7%) (SAMHSA, 2020). The population is ages 18 -25.  
Overdose and opi[INVESTIGATOR_578345], comparing Appalachian and non -Appalachian 
portions of states, ages 15 to 64 in 2015, 59.7% of diseases of despair were related to overdose 
of opi[INVESTIGATOR_2438]. WV has no non- Appalachian portions of the state (Meit et al., 2017) . 
Nationally, 1.[ADDRESS_760032] year ((2019 National Survey on Drug Use and Health, 2020).  
.  
 
 
  Page  16  Significance to Nursing  
This grant proposal is based on holistic nursing research principles (Helming et al., 2022) , 
including work with a marginalized population of those in recovery for substance use disorder 
(SUD) in north central Appalachia. This study also aligns with National Institutes of Health (NIH) 
National Center for Complementary and Integrative Health (NCC IH) standards to advance the 
evidence base for integrative complementary therapi[INVESTIGATOR_578346] a whole 
person health approach (NCCIH, 2021). The pos itive impact of this aromatherapy intervention is 
to increase comfort and ease, while reducing stress.  
 
Background    
West Virginia is at the epi[INVESTIGATOR_578347] a family left 
untouched by [CONTACT_578363] (Governor’s Council on Substance Abuse Prevention and Treatment, 2020; Saloner et al., 2019). Compared to the rest of the U nited 
States, West Virginians are disproportionately affected by [CONTACT_578364] “diseases of despair”, such as drug overdose (Merino et al., 2019; SAMHSA, 2018). Those who make it into recovery programs are often plagued by [CONTACT_578365] (Cicero & Ellis, 2017; Johannessen et al., 
2019; Yang et al., 2020) with the most common concurrent mental health issues being depressive disorder, stress, and anxiety (Hutton et al., 2017; Roos et al., 2020). Relapse prevention is key (SAMHSA, 2018). It is recommen ded that aromatherapy (such as using an 
aroma stick  with bergamot essential oil) has the potential to support those in recovery (Wesa, 
2004).  
 
Substance use disorder is characterized by a cluster of physiological, behavioral, and cognitive symptoms occurring when recurrent use of alcohol and/or drugs causes significant impairment, disability, and failure to meet major responsibilities (SAMHSA, 20 18; World Health Organization 
[WHO], 1992). Those in treatment have identified that increasing the level of comfort during substance use recovery is vital (Yang et al., 2020). Integrating aromatherapy could help improve perception of comfort and ease and r educe stress which could support healthy choices and 
encourage recovery program progression.  
 Aromatherapy has long been used as a non -pharmacologic treatment alongside medical 
treatments for various health conditions (Armstrong et al., 2019; Buckle, 2015; Coelho et al., 2017; Herz, 2009; Lizarraga- Valderrama, 2021; Perry & Perry, 2006). Specifically, bergamot 
(Citrus bergamia) essential oil (natural plant based oil) has been reported as one of the most 
commonly used essential oils because of its effectiveness, low price point, and safety when used via inhalation (Chang & Shen, 2011; Han et al., 201 7; Navarra et al., 2015). Bergamot 
essential oil has the ability to bind to GABAergic receptors and influence the hypothalamic -
pi[INVESTIGATOR_2117] -adrenal axis (HPA) providing possible explanation for it anxiolytic properties (Morrone 
et al., 2007; Saiyudthong & Marsden, 2011). Over the decades, bergamot essential oil has been 
successfully among persons with mood alterations including anxiety, depression, and stress 
(Lizarraga- Valderrama, 2021; Mannucci et al., 2017; Perry & Perry, 2006; Scuteri et al., 2017).  
 
 
  Page  17  Objectives  
Purpose:  
The purpose of the study is to examine the effect of an aromatic intervention using bergamot 
essential oil on comfort, ease, and stress in adults in a SUD recovery program.  
 
Primary Objectives & Aims:  
The innovation of this study is to use bergamot essential oil to improve perception of comfort 
and ease and reduce stress among the marginalized population in a SUD recovery program in rural Appalachia.  
 
Specific Aim #1: Pi[INVESTIGATOR_578348] a substance use 
disorder recovery program.  Hypothesis 1a:  Participants in the intervention group will report higher scores on comfort and 
ease than those in the control group.  
Hypothesis 1b:  Participants in the intervention group will report lower scores in stress than 
those in the control group.  
 Specific Aim #2: Evaluate the feasibility and acceptability of an aromatherapy intervention by [CONTACT_578366], enrollment and retention rates, intervention fidelity, and cost analysis.  
 
Study Design & Methodology  
The study uses a parallel -randomized control group comparison design. Data will be collected 
from participants daily and post intervention.  For Aim #1, descriptive and bivariate analysis will be conducted. Statistical assumptions will be tested. Sample demographics will be reported.  
For Aim #2, descriptive statistics will be used as well as participant recruitment, enrollment, and retention rates. Reasons for non -participation and attrition will be recorded. Percentage of 
intervention consistency will be calculated,  and cost of the intervention will be determined.  
 
Risk 
This study is only minimal risk because it involves aroma of a citrus essential oil named 
Bergamot. This essential oil is impregnated on a pure cotton wick within a manufacturer -sealed 
aroma inhaler. Participants are instructed and will demonstrate back to  the researcher that 
they will use the inhaler in the prescribed fashion. Participants encounter odors and aromas 
during  daily life and the anticipated magnitude of harm or discomfort anticipated in the 
 
 
  Page  [ADDRESS_760033] me, 
Marian Reven, at [EMAIL_11000] for further instructions.  
 
This study does include surveys that ask questions about feelings of comfort, ease, and stress. 
This may cause distress to some participants. Should a participant experience or express any psychological distress or disclose information that indicates a nee d for urgent psychological or 
clinical care, the researcher will connect the participant with their provider.  
 
Benefits  
The participant  may or may not directly benefit from participating in this research.  The 
knowledge gained from this study may eventually benefit others.  
Statistical Analysis Plan  
Data analysis For Aim 1, Descriptive (frequencies, means, ranges, standard deviations) and bivariate analysis will be conducted on the demographics, GCQ, Ease measure, and DASS scales. Statistical assumptions (i.e., normal distribution and homogeneity of v ariances etc.) will be 
tested. Sample demographics of patients will be reported. Fisher's exact test will be used for categorical variables; Repeated measures ANOVA and paired t -test will be used for continuous 
variables. Pearson's and Spearman's correlation analyses will be used to explore relationships among variables (Pallant, 2020) . The statistical significance is set at a 5% (alpha = 5%). All 
analyses will be completed using Statistical Package for the Social Sciences (IBM SPSS).  
 For Aim 2, Descriptive statistics will be used to analyze Aim 2a. Participant recruitment, enrollment, and retention rates will be tabulated and reported. Reasons for non- participation 
and attrition will be recorded and will be used to develop strategies t o address this. For Aim 2b, 
adherence to the intervention protocol will be calculated from responses in the logbooks. For Aim 2c, to determine the cost of the intervention implementation, all charges related to implementation are calculated. This includes costs of personnel time for administering each session, the materials, and incentives.  
 
Sample Size  
Sample size was calculated using G*Power v.[IP_ADDRESS] on repeated measure ANOVA given α =0.05, 
moderate effect size (0.25), power of 80%, two groups with 2 measurements, correlation among repeated measures (0.50), a total sample size of 98 will be required. A total sample size of n=49 for intervention group and n=[ADDRESS_760034] encrypted computer.  
 
Safety Monitoring & Unanticipated Event Reporting  
This study involves use of an aroma inhaler. This study is only minimal risk because it involves aroma of a citrus essential oil named Bergamot. This essential oil is impregnated on a pure cotton wick within a manufacturer -sealed aroma inhaler. Participants are instructed and will 
demonstrate back to  the researcher that they will use the inhaler in the prescribed fashion.  
 Participants encounter odors and aromas during daily life and the anticipated magnitude of harm or discomfort anticipated in the research is not greater in and of itself than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.  
 Participants will have an informational session with a Registered Aromatherapi[INVESTIGATOR_541], Marian Reven, who will demonstrate use and care of the aroma inhaler.  
The following reminder is provided in writing for participants.  
 *(When not in use, recap to close & store in a cool, dry place away from children and pets) It is OKAY to keep your closed inhaler in your pocket or purse and at room temperature   
Do not tamper with the packaging. Keep out of reach of children and animals. If you develop any adverse reactions such as a headache, stop, recap inhaler, and retry a little later. If unpleasant effects, such as headache continue, discontinue use and conta ct Marian Reven, Co -
Investigator at [EMAIL_11000]
  
 Every effort has been made to ensure the safety of all Participants and those at the study site.  
1. Aroma inhalers are factory sealed  
2. Tamper resistant packaging is used  
3. Safety data sheets are available  online and on site  
4. Inhalation of essential oils such as Bergamot is considered low risk  
5. Specific instructions are provided  
6. A Registered Aromatherapi[INVESTIGATOR_578349]. Participants are already in the care of medical staff.  
 
 
  Page  20  Study Duration & Timeline  
Task  March to 
June [ADDRESS_760035] to 
December  
2022  January to 
March 2023  April to May 
2023  
Create grant documents  X     
Finalize & refine grant 
application and submit  X      
Submit proposal to WVU 
IRB, make revisions as 
needed   X     
Complete BMED 
research & recruitment 
form    X   
Enrollment & run study    X   
Complete enrollment & 
run data     X  
Dissertation defense & 
graduate      X 
 
Informed Consent Process  
Participation in this study is contingent upon informed and ongoing consent by [CONTACT_578367]. They are free to withdraw from the study at any time without any repercussion.  
The following pi[INVESTIGATOR_578350]:  
 Will collect the following listed data  
Name  
[CONTACT_578383], the following  
Data will be collected from the chart and from survey (self -report)  
1. Identifier variables of Comfort, Ease, and Stress  
2. Stage of treatment in the SUD treatment program (Chart)  
3. Presence of anxiety and/or depression (Chart)  
4. Presence of severe mental illness Dx (Chart)  
5. Allergies to citrus fruits such as grapefruit, lemon, orange, or bergamot (Chart and self report)  
 
 
  Page  21  6. Previous experience with any integrative or complementary therapi[INVESTIGATOR_578351], massage, 
acupuncture, aromatherapy with essential oils, herbal preparations, meditation, mindfulness practices (Self -report)  
7. Pregnant and/or nursing (Self -report)  
8. Severe breathing problems such as asthma, chronic bronchitis, or COPD (Chart and self -
report)  
9. Report of sense of smell (self -report)  
10. Dx of a problem with sense of smell (Chart and self -report)  
11. Current illness with cold, flu, or covid (Self -report)  
 
Informed Consent Process  
See Appendix F  
Confidentiality & Privacy  
Subjects  in this research study will not be anonymous but all study participant data and 
information will be de -identified. Upon enrollment, participants will be given a unique identifier 
by [CONTACT_578368]. A master spreadsheet will be maintained to identify each participant by [CONTACT_578369]. All study data will be kept 
securely in a locked office.  
 Data will be kept for a minimum of [ADDRESS_760036]. Roger Carpenter,  or Co -I’s, Marian 
Reven, and Amanda Newhouse  
. 
The results of this work could be published or presented without any participant identifiers.  
 Other research purposes include reviewing the safety and feasibility of the aromatic intervention and developi[INVESTIGATOR_007] a better understanding of disease,  improving the design of future 
clinical trials.  
 
 
  Page  22  Supplies Available for Enrolling Participants (Kept i n Locked Office):  
1. Supply of prescreening surveys  
2. Master Log Sheet (MLS) for recording Participant name [CONTACT_114040]  
3. Master Random Number Table (RNT) for randomization  
4. Tote with Study Packets  (including surveys*)  
5. Extra forms  
6. Aroma inhalers ** 
 
*Surveys Used in this Study (See Appendix A)  
Surveys in this study include:  
1. Prescreening survey for the aromatic elements of the study  
2. Generalized Comfort Questionnaire (GCQ)  
3. Ease Measure  
4. Depression, Anxiety, and Stress Scale (DASS)  
5. Post survey for aromatic elements of the study  
 
**Aroma Inhalers Used in this Study (See Appendix B)  
1. Company supplying: Plant Extracts International https://plantextractsinc.com/   
2. Bergamot essential oil is used  
3. No direct contact [CONTACT_578370]  
4. No ambient odor should be present as inhalers are factory sealed and enclosed in 
tamper resistant packaging  
 
Contents of Study Packets  
1. Aroma inhaler  
2. Aethereo®Stick Information Sheet  
3. Cover  letter (Appendix C) 
4. Consent forms (2 copi[INVESTIGATOR_014])  
5. Pre surveys (Comfort, Ease, and Stress)  
6. Logbook s for Intervention or  Control Groups  (Appendix D) 
7. Reminder paper (Appendix E) 
8. [ADDRESS_760037] surveys (Comfort, Ease, Stress, Post Aroma)  
  
 
 
  Page  23  Prior to opening a  Study Packet  
1. In a private location, Enroller will determine eligibility for this study.  
a. Inclusion criteria are as follows:  
i. Older than [ADDRESS_760038] completed intensive phase 1 and wish to continue with treatment  
iv. Alert & oriented  
v. Able to provide written consent  
vi. Able to read & write English  
b. Exclusion criteria are as follows:  
i. Diagnosed with severe mental illness  
ii. Medical history of asthma 
iii. Other serious respi[INVESTIGATOR_578352]. Known allergy to citrus  
2. In a private location, Enroller will prescreen using created survey tool (a ppendix A) 
a. Use the prescreening survey provided  
b. Read prescreening survey to participants and record answers  
c. If not contraindicated by [CONTACT_578371], allow participant to smell the 
aroma inhaler (3 inches from nose)  
i. Record all reactions, “liked the smell”, “sneezed”, “said ‘yuck’” on the presurvey. Record “no negative reactions” as applicable (This is a vital component of aromatic research)  
3. IF PARTICIPANT IS INELIGIBLE,  thank them for their time, note on MLS that they were 
screened and why they were ineligible. Use the special section at the end of the MLS to make this notation. Do not use an Id # space. Write “ineligible” and the date across the 
top of the survey.  
4. IF PARTICIPANT IS ELIGIBLE , file prescreening form in predetermined place and obtain a 
study packet in the order they are arranged (001 -098)  
a. Enter date and name [CONTACT_578384] (RNT)  sheet  
5. Record Unique Identifier packet number on Master Log Sheet (MLS)  
a. Use MLS to track Participants  
b. This Unique Identifier number is already on every document in each packet  
 
Study Packet is Opened  
6. The study packet is opened in the presence of the study participant and contents of the folder are reviewed  Contents of Study Packets : 
a. Left pocket:  
i. Aroma inhaler  
ii. Welcome letter  
iii. Consent form x 2  
iv. Pre-Surveys (Comfort, Ease, and Stress)  
 
 
  Page  24  b. Right pocket:  
i. Logbook  
ii. Reminder paper (To post as a reminder) ADD DATES 
iii. Closed postage paid envelope  
 
7. Consent form is reviewed and signed  
8. Pre-surveys for Comfort, Ease, and Stress  are completed  
Use of the Aethereo®Stick is reviewed  (Appendix B for details about inhaler) : 
a. Enroller will either open or have participant open the sealed package for the 
Aethereo®Stick (aroma inhaler) open the outer sealed package  
b. Save the package for storage  
c. Pi[INVESTIGATOR_578353]  
d. There is no need to shake the inhaler  
e. Breath out gently  
f. While holding the inhaler about 3 inches (7.62 cm) from the nose  
g. Inhale through the nose using [ADDRESS_760039] sunlight, children, and pets.  
k. NOTE: The Enroller will record all reactions to participant exposure to the aroma inhaler. Verbatim recording of any negative or positive response is vital. This is recorded on the Prescreening survey at the bottom of the form. Any negative or adverse reac tion must be recorded. If no negative reaction, then the Enroller 
must write, “No negative reaction”  
9. As needed use :  
a. The inhaler may be used more than [ADDRESS_760040] all uses and reasons for uses in the provided logbook 
10. Use other than instructed:  
a. If the participant uses the inhaler in some other fashion than instructed, they are asked to record this information as well (i.e. inhales x 10, inserts into nostril 
[which is considered safe], uses a different count to exhale etc.)  
11. How Participant  begin s intervention:  
a. The participant begins the 7 -day intervention at the beginning of their next full 
day of life (This allows for those who work nights etc.)  
i. ADD DATES: Participants (preferrable to have participants do this and not the Enroller) will add dates to pages of the logbook (e.g., If they received their packet and instructions on October 11, then they should begin their study on the NEXT FULL DAY, Oct ober 12, and their study would be 
 
 
  Page  [ADDRESS_760041] the 7 -days of the 
study, 10/12, 10/13 and so forth to 10/18)  
b. Three times daily means spaced out in 3 times, which could mean morning, 
afternoon, and evening, or anything else that is separated by [CONTACT_3450] 4 -6 
hours (while awake)  
c. On day 1, 2, & [ADDRESS_760042] the 
researcher with any questions.  
d. Days 4, 5, 6, & 7, participants will not receive reminders.  
i. A reminder will be sent on day 7.  
ii. After day 7, all participants will open their final survey packet included in 
the folder.  
iii. They will be instructed to complete the survey packet and return it and 
the logbook using the prepaid postage envelope.  
  
 
 
  Page  [ADDRESS_760043] in Participant Packet:  
INTERVENTION:  
iv. Those randomized to the Intervention group 
1. Left pocket (in this order)  
a. Aroma inhaler  
b. Aethereo®Stick information sheet  
c. Welcome letter  
d. Copy of consent  
2. Right pocket (in this order)  
a. Logbook (with dates written in)  
b. Reminder paper  
c. Postage paid envelope (with date and instructions for 
return on note attached to front of the envelop)  
CONTROL:  
v. Those randomized to the Control group (The AROMA INHALER from Control group packets is labeled with participants ID# and kept in a secure location until they complete the study. It will have been opened and demonstrated with the participant during study in troduction)  
1. Left pocket (in this order)  
a. Welcome letter  
b. Copy of consent  
2. Right pocket (in this order)  
a. Logbook (with dates written in)  
b. Reminder paper  
3. Postage paid envelope (with date and instructions for return on note attached to front of the envelope ) 
  
 
 
  Page  27  How Participants are Returning Study Materials:  
Postage paid envelop is marked “Complete the Logbook and the surveys and return them ALL 
on _______.” Add date they will complete the 7 -day study  
e. (e.g., If they received their packet and instructions on October 11, then they should begin their study on the NEXT FULL DAY, October 12, and their study would be complete on October 19. October 19 is the date entered on the note attached to this envelope)  
 
Timing Of Gift Card  
Once the final survey is received, the $[ADDRESS_760044] will be issued to the intervention group and 
the $[ADDRESS_760045] and inhaler to the control group.    
 
 
  Page  28  Frequently Asked Questions:  
What if a Participant Loses Their Aroma Inhaler?  
Participants are instructed to contact [CONTACT_578372] [EMAIL_11000]   if they lose 
their inhaler and arrange for a replacement.  
• The study will continue  during the time they are without an inhaler and resume when 
they have one.  
• The researcher will note this occurrence, but data analysis will occur as if the days were 
consecutive.  
 
What if a Participant has a Reaction?  
Participants are instructed to contact [CONTACT_578372] [EMAIL_11000]  if they 
experience adverse reactions such as a headache.  
• They are asked to stop using the inhaler, recap it, and retry the inhaler as directed a 
little later.  
• If unpleasant effects, such as headache continue, discontinue use,  and contact [CONTACT_578373], Investigator at [EMAIL_11000]   
• If participant feels any severe reaction like difficulty breathing, they are asked to seek 
medical care  
 
What if a Participant Wants to Withdraw from the Study?  
Participants are instructed to contact [CONTACT_578372] [EMAIL_11000]  if they wish 
to withdraw from the study.  
• They are free to withdraw from the study at any time without penalty  
• They can keep the aroma inhaler and all study materials  
• They are asked to return the logbook  if they completed it 
• They will not receive the $[ADDRESS_760046]  
   
 
 
  Page  29  References  
Armstrong, M., Flemming, K., Kupeli, N., Stone, P., Wilkinson, S., & Candy, B. (2019). 
Aromatherapy, massage and reflexology: A systematic review and thematic synthesis of 
the perspectives from people with palliative care needs. Palliative Medicine , 33(7), 757–
769. https://doi.org/10.1177/0269216319846440 
Buckle, J. (2015). Clinical aromatherapy: Essential oils in healthcare  (3rd ed.). Elsevier.  
Chang, K. M., & Shen, C. W. (2011). Aromatherapy benefits autonomic nervous system 
regulation for elementary school faculty in Taiwan. Evidence -Based Complementary and 
Alternative Medicine , 2011, 1–7. https://doi.org/10.1155/2011/946537 
Cicero, T. J., & Ellis, M. S. (2017). The prescription opi[INVESTIGATOR_15817]: A review of qualitative 
studies on the progression from initial use to abuse. Dialogues in Clinical Neuroscience , 
19(3), 259–269.  
Coelho, A., Parola, V., Cardoso, D., Bravo, M. E., & Apóstolo, J. (2017). Use of non-
pharmacological interventions for comforting patients in palliative care: A scopi[INVESTIGATOR_578354]. JBI Evidence Synthesis , 15(7), 1867–1904. https://doi.org/10.[ZIP_CODE]/JBISRIR -
2016- 003204 
Governor’s Council on Substance Abuse Prevention and Treatment. (2020). West Virginia 2020-
[ADDRESS_760047] Virginia Department of Health & Human 
Resources Office of Drug Control Policy. https://dhhr.wv.gov/office -of-drug- control -
policy/news/Documents/FINAL%20-
%20West%20Virginia%202020_2022%20Council%20Substance%20Use%20Plan_Janu
ary%2020,%202020%20(as%20f iled).pdf  
 
 
  Page  30  Han, X., Gibson, J., Eggett, D. L., & Parker, T. L. (2017). Bergamot (Citrus bergamia) essential 
oil inhalation improves positive feelings in the waiting room of a mental health treatment 
center: A pi[INVESTIGATOR_799]. Phytotherapy Research , 31(5), 812–816. 
https://doi.org/10.1002/ptr.5806 
Helming, M. A. B., Avino, K., Shields, D., Rosa, W., & Dossey, B. M. (Eds.). (2022). Dossey & 
Keegan’s holistic nursing: A handbook for practice  (8th ed.). Jones & Bartlett Learning. 
Herz, R. S. (2009). Aromatherapy facts and fictions: A scientific analysis of olfactory effects on 
mood, physiology and behavior. International Journal of Neuroscience , 119(2), 263–290. 
https://doi.org/10.1080/00207450802333953 
Hutton, H., Lesko, C. R., Chander, G., Lau, B., Wand, G. S., & McCaul, M. E. (2017). 
Differential effects of perceived stress on alcohol consumption in moderate versus heavy drinking HIV -infected women. Drug and Alcohol Dependence , 178, 380–385. 
https://doi.org/10.1016/j.drugalcdep.2017.05.021  
Johannessen, D. A., Nordfjærn, T., & Geirdal, A. Ø. (2019). Change in psychosocial factors 
connected to copi[INVESTIGATOR_578355]: A systematic review. Substance Abuse Treatment, Prevention, and Policy , 14(1), 16. 
https://doi.org/10.1186/s13011- 019-0210- 9 
Kalayasiri, R., Maneesang, W., & Maes, M. (2018). A novel approach of substitution therapy 
with inhalation of essential oil for the reduction of inhalant craving: A double -blinded 
randomized controlled trial. Psychiatry Research , 261, 61–67. 
https://doi.org/10.1016/j.psychres.2017.12.015  
Lizarraga‐Valderrama, L. R. (2021). Effects of essential oils on central nervous system: Focus on 
mental health. Phytotherapy Research , 35(2), 657 –679. https://doi.org/10.1002/ptr.6854 
 
 
  Page  31  Mannucci, C., Navarra, M., Calapai, F., Squeri, R., Gangemi, S., & Calapai, G. (2017). Clinical 
pharmacology of citrus bergamia: A systematic review: Systematic review of citrus 
bergamia clinical studies. Phytotherapy Research , 31(1), 27–39. 
https://doi.org/10.1002/ptr.5734 
Meit, M., Heffernan, M., Tanenbaum, E., & Hoffman, T. (2017). Appalachia diseases of despair  
(p. 23) [Policy Analysis and Research]. Appalachian Regional Commission. https://www.arc.gov/wp-content/uploads/2020/06/AppalachianDiseasesofDespairAugust2017.pdf  
Merino, R., Bowden, N., Katamneni, S., & Coustasse, A. (2019). The opi[INVESTIGATOR_578356]. The Health Care Manager , 38(2), 187–195. 
https://doi.org/10.1097/HCM.0000000000000256 
Morrone, L. A., Rombolà, L., Pelle, C., Corasaniti, M. T., Zappettini, S., Paudice, P., Bonanno, 
G., & Bagetta, G. (2007). The essential oil of bergamot enhances the levels of amino acid 
neurotransmitters in the hippocampus of rat: Implication of monoterpe ne hydrocarbons. 
Pharmacological Research, 55(4), 255–262. https://doi.org/10.1016/j.phrs.2006.11.010 
Navarra, M., Mannucci, C., Delbò, M., & Calapai, G. (2015). Citrus bergamia essential oil: From 
basic research to clinical application. Frontiers in Pharmacology , 6. 
https://doi.org/10.3389/fphar.2015.[ZIP_CODE]  
NCCIH. (2021). NCCIH strategic plan fiscal year 2021–2025. 
https://www.nccih.nih.gov/about/nccih- strategic -plan-2021- 2025  
Pallant, J. (2020). SPSS survival manual: A step by [CONTACT_578374]. 
https://www.taylorfrancis.com/books/9781003117407 
 
 
  Page  32  Perry, N., & Perry, E. (2006). Aromatherapy in the management of psychiatric disorders. CNS 
Drugs , 20(4), 257–280. https://doi.org/10.2165/00023210- 200620040- [ZIP_CODE] 
Redstone, L. (2015). Mindfulness meditation and aromatherapy to reduce stress and anxiety. 
Archives of Psychiatric Nursing , 29(3), 192–193. 
https://doi.org/10.1016/j.apnu.2015.03.001 
Roos, C. R., Kiluk, B. D., McHugh, R. K., & Carroll, K. M. (2020). Evaluating a longitudinal 
mediation model of perceived stress, depressive symptoms, and substance use treatment 
outcomes. Psychology of Addictive Behaviors , 34(6), 660–668. 
https://doi.org/10.1037/adb0000581 
Saiyudthong, S., & Marsden, C. A. (2011). Acute effects of bergamot oil on anxiety- related 
behaviour and corticosterone level in rats. Phytotherapy Research , 25(6), 858–862. 
https://doi.org/10.1002/ptr.3325 
Saloner, B., Landis, R., Stein, B., & Barry, C. L. (2019). The Affordable Care Act in the heart of 
the opi[INVESTIGATOR_8562]: Evidence from West Virginia. Health Affairs (Project Hope) , 38(4), 
633–642. https://doi.org/10.1377/hlthaff.2018.[ZIP_CODE] 
SAMHSA. (2018). SAMHSA releases national survey on drug use and health. Capi[INVESTIGATOR_578357]. https://www.thenationalcouncil.org/capi[INVESTIGATOR_29106] -connector/2018/09/samhsa -
releases -national -survey -on-drug- use-and-health/  
SAMHSA. (2020). Behavioral health barometer: West Virginia, volume 6. Indicators as 
measured through the 2019 national survey on drug use and health and the national survey of substance abuse treatment services  (p. 45) [HHS Publication No. SMA –20–
Baro –19–WV]. https://store.samhsa.gov/  
 
 
  Page  33  Scuteri, D., Morrone, L. A., Rombolà, L., Avato, P. R., Bilia, A. R., Corasaniti, M. T., Sakurada, 
S., Sakurada, T., & Bagetta, G. (2017). Aromatherapy and aromatic plants for the 
treatment of behavioural and psychological symptoms of dementia in patients with Alzheimer’s disease: Clinical evidence and possible mechanisms. Evidence- Based 
Complementary and Alternative Medicine , 2017, 1–9. 
https://doi.org/10.1155/2017/9416305 
Wesa, K. M. (2004). Recommendations and guidelines regarding the preferred research 
protocol for investigating the impact of an optimal healing environment on patients with substance abuse . 10(S1), S -193-S-199. 
World Health Organization (Ed.). (1992). The ICD -10 classification of mental and behavioural 
disorders: Clinical descriptions and diagnostic guidelines . World Health Organization.  
Yang, Y., Perkins, D. R., & Stearns, A. E. (2020). “I started to feel better now”: Qualitative 
findings from client narratives on early recovery in inpatient substance use treatment. 
International Journal of Mental Health & Addiction, 18(4), 1048–1066. https://doi.org/10.1007/s11469- 019-[ZIP_CODE]- z 
   
 
 
  Page  34  Appendix A  
PRESCREEN SURVEY  
To be completed by [CONTACT_578375]:  
1. Please answer the following questions about a version (dislike) or allergy .  
a. Do you have a strong aversion to smells of citrus and/or citrus fruit(s) themselves 
(such as grapefruit, orange, lemon, or bergamot). Yes/No (If no, please go to the 
next question)  
i. Do you have any allergies to citrus? Yes/No (If no, answer next question)  
ii. This study uses the pure essential oil of Bergamot. Have you ever smelled this fruit or essential oil? Yes/No  
iii. If yes, you have smelled Bergamot fruit or essential oil, do you dislike the 
smell? Yes/No  
iv. If yes, you dislike the smell of Bergamot essential oil, you are excused from participation in this study.  
 
If yes, you have a  strong dislike or allergy to Bergamot fruit or essential oil, you are not 
eligible to participate in this study.  
 
If no strong aversion or allergy to Bergamot, proceed with the following questions.  
 
2. Do you or have you ever been told by a doctor that you have any of the following medical or health conditions? Yes/No (If No, go to question 3 ) 
a. ___ Severe breathing problems such as asthma, chronic bronchitis, or a chronic obstructive pulmonary disease (COPD)  
b. ___ Pregnant or the possibility of becoming pregnant and/or breastfeeding  
c. ___ Allergies to citrus fruits such as grapefruit, lemon, orange, or bergamot  
 
If yes to any responses to question 2, you are not eligible to participate in this study.  
3. Have you ever tried any integrative or complementary therapi[INVESTIGATOR_014] (examples include; 
massage, yoga, acupuncture, aromatherapy with essential oils, herbs, meditation, mindfulness practices etc.) Yes/No (If Yes, please answer the following. If No, go to questio n 5) 
a. If yes, list which ones? ______________________________  
b. If yes, what was your main reason for using complementary therapi[INVESTIGATOR_014]? Choose all that apply  
i. ___Pain  
ii. ___Anxiety  
iii. ___Relaxation  
iv. ___Stress relief  
 
 
  Page  35  v. ___Other, please write in ______________  
c. If there is a specific therapy used for a specific symptom, please write the 
therapy beside the symptom listed above.  
d. On a scale of 0 to 10 with 0 being not at all effective and 10 being very effective, how effective was the therapy noted above for relief of the symptom? (Example: Pain, massage, 7/10)  
 
4. Was one of the complementary therapi[INVESTIGATOR_578358]? 
Yes/No (If Yes, please answer the following. If No, go to question 5 ) 
a. No, I have not used aromatherapy or essential oils. (Proceed to question 5) 
b. Yes, I have used essential oils and have tried (please list the essential oils you 
have tried) ______________  
c. Of those essential oils you have tried, which one or ones would you consider to 
be your favorite(s) _______________  
d. Of those essential oils you have tried, which one or ones would you consider to 
be your least favorite(s) ______________  
e. Have you ever tried Bergamot essential oil? Yes/ No  
i. If yes, why did you try it? _____________  
If yes, what, if any effect, did you think it had? _____________  
 
5. Do you have difficulty smelling or recognizing odors? Yes/No  
a. If yes, do you think your problems with smelling are because of allergies or stuffy 
nose and congested sinuses? Yes/No  
i. Are you currently feeling sick with a cold, the flu, or with COVID? Yes/No  
b. If yes, you have problems with your sense of smell, have you ever been told by a 
doctor that you have a problem with your sense of smell? Yes/No  
i. If yes, have you ever been diagnosed or told by a doctor that you have anosmia, which is a total loss of the sense of smell? Yes/No  
1. Was this loss of smell related to COVID or some other illness? Yes/No  
If yes, approximately when did the loss of smell begin ____  
END OF SURVEY  
 Participant is not eligible to participate in this study  
If they answered “Yes” to either or both of the following questions:  
Question 1. "I am allergic to or have a strong aversion to smells of citrus and/or citrus fruit(s) 
themselves (such as grapefruit, orange, lemon, bergamot) ” 
Question 2. “Do you or have you ever been told by a doctor that you have any of the following 
medical or health conditions”, and/or  
 ENROLLER: Record all reactions to the smell of Bergamot during prescreening. If no negative reaction, write “No negative reaction” ___________________________  
 
 
 
  Page  36  Once complete, either excuse participant if they are not eligible or proceed by [CONTACT_19201] a 
packet and opening study materials.  
   
 
 
  Page  37  COMFORT SURVEY  
Thank you VERY MUCH for helpi[INVESTIGATOR_578359] . Below are statements that relate to 
your comfort right now. Six numbers are provided for each question; please circle the number you think 
most closely matches your feeling. Your responses should describe your comfort right now.  
Right now…  Strongly Disagree    Strongly Agree  
1. My body is relaxed right now  [ADDRESS_760048] found meaning in my life  1 2 3 4 5 6 
28. I need to feel good again  1 2 3 4 5 6 
 
EASE MEASURE  
Ease Measure: Please circle the number ( never; sometimes; frequently; always ) to indicate your degree 
of agreement with each statement as a descriptor of what is generally happening in your everyday life.  
       
 Never  Sometimes  Frequently  Always  
1. I can let go of my daily stress.  
 [ADDRESS_760049] week. There are no right or wrong answers. Do not spend too much time on any statement.  
 The rating scale is as follows:  
[ADDRESS_760050] to wind down  
 0 1 2 3 
2. I was aware of my dry mouth  
 0 1 2 3 
3. I couldn’t seem to experience any positive feelings at all  
 0 1 2 3 
4. I experienced breathing difficulty (e.g. excessively rapid breathing, 
breathlessness in the absence of physical exertion)  [ADDRESS_760051] to situations  
 0 1 2 3 
7. I experienced trembling (e.g. in the hands)  
 [ADDRESS_760052] to  
 0 1 2 3 
11. I found myself getting agitated  
 0 1 2 3 
12. I found it difficult to relax  
 0 1 2 3 
13. I felt down -hearted and blue  
 0 1 2 3 
14. I was intolerant of anything that kept me from getting on with what 
I was doing  0 1 2 3 
15. I felt I was close to panic  
 0 1 2 3 
16. I was unable to become enthusiastic about anything  
 0 1 2 3 
17. I felt I wasn’t worth much as a person  
 0 1 2 3 
18. I felt that I was rather touchy  
 0 1 2 3 
19. I was aware of the action of my heart in the absence of physical 
exertion (e.g. sense of heart rate increase, heart missing a beat)  [ADDRESS_760053] SURVEY  
 
Please answer the following regarding the intensity or strength of the aroma inhaler.  
 
1. On a scale of 1 to 10 rate overall how enjoyable the aroma of the inhaler was (0 being 
not enjoyable at all and 10 being very enjoyable)  
0 1 2 3 4 5 6 7 8 9 10 
 
2. On a scale of 1 to 10 rate the usual  strength smell of the aroma inhaler ([ADDRESS_760054] it could be)  
0 1 2 3 4 5 6 7 8 9 10 
 
3. How likely are you to continue to use this aroma inhaler ( 1 being not at all likely and 10 
being very likely) ? 
0 1 2 3 4 5 6 7 8 9 10 
 
 
  Page  41   
4. Any other thoughts you wish to share about this experience?  
 
 
Thank you for taking the time to complete this study, please return this and all other surveys 
and the logbook in the prepaid envelope. Once this is received, a gift card will be sent.  
If you have any further questions, please contact [CONTACT_578372] [EMAIL_11000]  
  
 
 
  Page  42  Appendix B  
SAFETY DATA SHEET  
 
 

 
 
  Page  43  MANUFACTURER SAFETY DATA SHEET  
 
 
 

 
 
  Page  44  Safety Data Sheet and GAS CHROMATOGRAPHY/MASS SPECTROMETRY (GC/MS) 
 

 
 
  Page  [ADDRESS_760055] EXPI[INVESTIGATOR_578360]  49  Appendix C 
Cover Letter (Formatted per IRB) 
 
Dear Participant,  
 This letter is to inform you about the research project Using aromatherapy for comfort, ease, and stress for adults being treated for substance use disorder in north central Appalachia: A randomized controlled trial . This project is being conducted by [CONTACT_578376], MSN, RN in the 
Adult Health Department at the WVU School of Nursing. This study is done to fulfill the requirements of earning my PhD in nursing philosophy at WVU.  
 For this study, you will either be asked to answer survey questions, use an aroma inhaler, and fill out a daily logbook or asked to answer surveys, and fill out a daily logbook. The study has one group that uses the aroma inhaler and one group that does not, and this is r andomly 
assigned. The study lasts for [ADDRESS_760056] 3 days of the study  and at the end. You will receive a $[ADDRESS_760057] and an aroma inhaler valued at $[ADDRESS_760058] will be kept as confidential as legally possible. All data will be reported in the aggregate  (all together). Your participation is entirely voluntary. You may skip 
any question that you do not wish to answer, and you may stop participating at any time. The West Virginia University Institutional Review Board's approval of this project is on file with the WVU Office of Human Research Protections.   
 If you have any questions about this research project, please feel free to contact [CONTACT_318642] [EMAIL_11000]
. Additionally, you can contact [CONTACT_578377] 304- 293-7073.  Thank you for your participation.  
 Sincerely,  
  Marian Reven, MSN, RN  
  For more information, please see the informed consent.
 
V2019.05.23         Page  50 | 
86  
Appendix D 
Logbook s for Intervention & Control Groups  
 
ID#___________  
 
     
 
  
   
AROMA INHALER STUDY  
 
LOGBOOK  
 
INTERVENTION GROUP  
  
 
V2019.05.23         Page  51 | 
86  
 
Directions for using your aroma inhaler and this logbook:  
Follow these steps to use your aroma inhaler:  
 
1. Hold the aroma inhaler by [CONTACT_362347]  
2. Twist off the cap. The inner part of the aroma inhaler with the essential oil- soaked 
cotton wick is part of a closed system and is not intended to be opened. All you need to do is twist off the cap  
3. Hold the aroma inhaler within 3 inches of your nose  
4. Breath in gently through your nose for 3 seconds  
5. Hold your beath for about three seconds and then exhale gently through your mouth  
6. Repeat this 3 times* and then replace the cap and store your aroma inhaler in a cool, dry place away from children or pets. (You may repeat this breathing cycle more than 3 times each day, please remember to make a note of this in the comments section about when and why you did)  
7. Use at least 3 times a day, and if you want to, use it more, but this should be recorded on the daily logbook page  
 Follow these steps to use your Logbook:  
Use your logbook to track how you are using your aroma inhaler and how you are feeling  
 
1. Use a new page of the logbook for each of the seven days of the study  
2. If you forget or purposely do not do the aroma inhaler, please make a note with a brief reason why  
3. Do not stop the study because you miss a step of using the inhaler or recording in the logbook  
4. Keep your logbook in a secure place as we will collect it at the end of the study  
5. Do not write important or private information that does not have to do with using your aroma inhaler in this logbook  
6. Do not write your name [CONTACT_578385]  
7. All information provided in the logbook will be kept confidential  
8. Return within 3 days of completion  
  *NOTE: If you develop any uncomfortable symptoms such as a headache, stop using the aroma inhaler, recap, and retry a little later. If unpleasant symptoms continue the next time, discontinue use and contact [CONTACT_578376], the Principal Investigator (PI), at [EMAIL_11000].  
     
 
V2019.05.23         Page  52 | 
86  
 
    Day 1  
 Please indicate each time you use your inhaler today (approximate time of day)  
 ____ I used my aroma inhaler as directed for the first time today  
____ I used my aroma inhaler as directed for the second time today  
____ I used my aroma inhaler as directed for the third time today  
 Any additional comments:  
If you used your aroma inhaler any extra times, please indicate when and brief reason why (example: 2:30p, feeling stressed, and it seemed to help)  
      One time at the end of each day, after using the inhaler throughout your day, place an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
 
 
If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  53 | 
[ADDRESS_760059] time today  
 Comments: (example: I used my aroma inhaler an extra time today because…)  
 
 
   One time each day place an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  54 | 
[ADDRESS_760060] time today  
 Comments: (example: I used my aroma inhaler an extra time today because…)  
 
 
   One time each day place an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  55 | 
[ADDRESS_760061] time today  
 Comments: (example: I used my aroma inhaler an extra time today because…)  
 
 
   One time each day place an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  56 | 
[ADDRESS_760062] time today  
 Comments: (example: I used my aroma inhaler an extra time today because…)  
 
 
   One time each day place an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  57 | 
[ADDRESS_760063] time today  
 Comments: (example: I used my aroma inhaler an extra time today because…)  
 
 
   One time each day place an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  58 | 
[ADDRESS_760064] time today  
 Comments: (example: I used my aroma inhaler an extra time today because…)  
 
 
   One time each day place an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  59 | 
86  
• Thank you for completing your seven- day aroma inhaler study!  
• Please place your survey and logbook in the envelope provided and seal it  
• Return this envelope to the Chestnut Ridge Center within 3 days of completion  
• Receive a $[ADDRESS_760065]  
• Keep the aroma inhaler and all other study materials as our way of saying thank you!  
  
 
V2019.05.23         Page  60 | 
86  
ID#___________  
 
        
 
 
 
AROMA INHALER STUDY  
 
LOGBOOK  
 
CONTROL GROUP  
  
 
V2019.05.23         Page  61 | 
86  
 
 Follow these steps to use your Logbook:  
Use your logbook to track your comfort on each of the seven days of the study  
  Day [ADDRESS_760066] an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
 
 
If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  62 | 
[ADDRESS_760067] an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  63 | 
[ADDRESS_760068] an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  64 | 
[ADDRESS_760069] an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  65 | 
[ADDRESS_760070] an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  66 | 
[ADDRESS_760071] an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  67 | 
[ADDRESS_760072] an X on the line under “I feel as comfortable as possible today”  
 I feel as comfortable as possible today  
  
Strongly disagree  
 Strongly agree  
  
 Comments:  
 
  If you have any questions or comments, contact [CONTACT_578372] [EMAIL_11000]. Thank you   
 
V2019.05.23         Page  68 | 
86  
• Thank you for completing your logbook for the seven- day aroma inhaler study!  
• Please place your survey and logbook in the envelope provided and seal it  
• Return this envelope to the Chestnut Ridge Center within 3 days of completion  
• Receive a $[ADDRESS_760073]  
• You will receive the aroma inhaler and all other study materials as our way of saying 
thank you!  
  
 
V2019.05.23         Page  69 | 
86  
Appendix E 
Reminder Paper  
SEVEN DAY AROMA INHALER STUDY   
(Please post this in a place where you will see it each day as a reminder to use your aroma 
inhaler and logbook) Thank you for your participation  
How to use & store your aroma inhaler*  
DIRECTIONS: To use 3 times daily and as desired:  
1. Uncap Inhaler  
 Hold within 3 inches of the nose  
2. Gently breath in through your nose and hold for 3 seconds, gently exhale through your 
mouth 
 Repeat 3 times each day and as desired (Use the comments section of the logbook to 
 record extra use and thoughts about using your aroma inhaler)  
3. Recap Inhaler & Record all uses & reactions to the inhaler in the Logbook**  
4. Keep your aroma inhaler and logbook in a safe place. The aroma inhaler is yours to keep.  
 **The logbook is returned at the end of this study  
*(When not in use, recap to close & store in a cool, dry place away from children and pets) It is 
OKAY to keep your closed inhaler in your pocket or purse and at room temperature   
Do not tamper with the packaging. Keep out of reach of children and animals. If you develop 
any adverse reactions such as a headache, stop, recap inhaler, and retry a little later. If  
 
V2019.05.23         Page  70 | 
[ADDRESS_760074] Marian Reven, 
Investigator at [EMAIL_11000]   
Thank you!  
  
 
V2019.05.23         Page  71 | 
86  
Appendix F 
Key Information for:  
Using aromatherapy for comfort, ease, and stress for adults being treated for substance use 
disorder in north central Appalachia: A randomized controlled trial  
 
You are being asked to participate in the research described below.  This page provides key 
information that may help you to make this decision; more detailed information can be found after this section.   
Why is this research being done and what is involved?  
• The purpose of this study is to see if using an essential oil called Bergamot will have any 
effect on your comfort, ease, and stress 
• You will be asked to use an aroma inhaler, which is a small container about the size of a 
lipstick container, that contains a small amount of pure essential oil, three times a day for one week. Surveys are completed at the beginning and at the end of the week. A daily logbook with a short checklist is also used. 
• The study lasts for one week (7 days) 
Do I have to participate and what are the risks involved?  
Participation in this research study is completely voluntary and you are free to withdraw from the 
research at any time.  If you do not wish to participate, please discuss alternatives with the researcher or refer to the “Alternatives” section in the consent form.  You may or may not directly benefit from participating in this research.  
Risks from participation in this study include having an adverse reaction to the essential oil of Bergamot that is contained in the aroma inhaler. Additionally, time spent completing surveys and a daily logbook may seem like it adds additional stress to the participant.  
 
V2019.05.23         Page  72 | 
[ADDRESS_760075] questions or concerns? 
If you have any questions or concerns about this research or would want to withdrawal from the 
study, you can contact [CONTACT_578372] [EMAIL_11000] from the School of Nursing at West Virginia University.  
 
For more information, please see the Informed Consent Form.  
 
 
 
  Page 31   
Informed Consent  for Research  | Minimal Risk  
 
Principal Investigator (PI) | [CONTACT_578390] (Marian Reven Dissertation work)  
Department |  School of Nursing 
Sponsor or Funding Source |  TBD  
WVU IRB Protocol # |  Pending 
Study Title |  Using aromatherapy for comfort, ease, and stress for adults 
being treated for substance use disorder in north central Appalachia: A randomized controlled 
trial   
Introduction  
You have been asked to participate in this research study, which has been explained to you by [CONTACT_578378].  This research is being conducted to fulfill the requirements for a [PhD] in [Philosophy of Nursing] from the Department of Nursing at West Virginia University.  This research is being conducted under the supervision of [CONTACT_578390]. 
Purpose  
The purpose of this study is to see if using an essential oil called Bergamot will have any effect on your comfort, ease, and stress.  WVU expects to enroll approximately [ADDRESS_760076], you will be pre -screen ed using a survey that includes questions about integrative or 
complementary therapi[INVESTIGATOR_014] (massage, yoga, acupuncture, aromatherapy with essential oils, herbs, 
meditation, mindfulness practices) . This survey also asks questions about allergies and sense of 
smell because this study involves smelling  aroma in the form of an essential oil called Bergamot .  
2. If a severe allergy or medical condition does not allow you to participate, the prescreening form will be destroyed, and you will be excused from further participation.  
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 1 3. If you qualify to be in the study, you will sign a consent form, and then receive a study packet.   
4. You will be randomly assigned to one of two groups. One groups will receive an aroma inhaler 
to use 3 x day for 7 days and complete a daily logbook. The other group will receive only the daily logbook. But those who do not get their aroma inhaler at the beginning of the study will receive it at the end of the study.  
5. Both groups will do surveys before the study, the logbook every day, and surveys after the study.  
6. The surveys include questions about overall comfort, ease, and stress.  
7. Once consent and pre- surveys are complete, you will be shown how to use the aroma inhaler 
correctly.  
8. The study lasts for 7 days and begins on the day after you sign the consents and receive your packet. (So, if you sign up on a Tuesday, you will start the study on Wednesday).  
9. At the end of [ADDRESS_760077] will be collected including s tage of treatment in the SUD treatment program, Presence of medical 
diagnoses of anxiety and/or depression, and presence of severe mental illness.   
12. Your permission to use your cell phone number to contact [CONTACT_578379] 1 through 3 and at the end of the study is requested (Optional). 
Risks and Discomforts 
Potential risks or discomforts include a dislike of the scent or possibly a headache because of 
inhaling the essential oil fragrance from the aroma inhaler. If headache or feeling of dislike continues the participant is asked to discontinue use of the arom a inhaler and contact [INVESTIGATOR_048], Marian 
Reven,  at [EMAIL_11000]
 for further instructions. Logbooks will still be collected, and a 
post survey provided. Those who complete the study, even if they must discontinue use of the aroma inhaler before the end will receive the gift card if study materials and surveys are retur ned and 
complete.  
This study does include surveys that ask questions about feelings of comfort, ease, and stress. This may cause distress to some participants. Should a participant experience or express any psychological distress or disclose information that indicates a need for urgent psychological or 
clinical care, the researcher will connect the participant with their provider.  
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 [ADDRESS_760078](s) or event.   
Alternative s   
You do not have to participate in this study.   
Benefits 
You may or may not directly benefit from participating in this research.  The knowledge gained from 
this study may eventually benefit others. 
Financial Considerations 
 
You will be compensated with a $[ADDRESS_760079] for completing this study.   
You will keep your aroma inhaler valued at $7.[ADDRESS_760080] Marian Reven at 
[EMAIL_11000]  . 
Your information may be provided to the appropriate parties for billing and/or payment purposes.  
Please be advised that any compensation received for participation in a research study, including a gift card, is considered taxable income and must be report ed to the Internal Revenue Service (IRS).  
Your data, health information, and research results , or any and all other information related to this 
research study used in this research study may contribute to a new discovery or treatment.  In some instances, your data, your health information, your research results, these discoveries or treatments, or any other information related to this research study, even if identifiers are removed, may be of 
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 [ADDRESS_760081] order or may be inspected by [CONTACT_578380], including the Food and Drug Administration (FDA), without your additional consent. 
In addition, there are certain instances where the researcher is legally required to give information to 
the appropriate authorities.  These would include mandatory reporting of infectious diseases, mandatory reporting of information about behavior that is imminently dangerous to you or to others, such as suicide, child abuse, etc.  
In any publications that result from this research, neither your name [CONTACT_578386]. 
HIPAA Authorization  
We know that information about your health is private. We are dedicated to protecting the privacy of that information. Because of this promise, we must get your written authorization (permission) before we may use or disclose your protected health information or share it with others. 
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 [ADDRESS_760082] on your access to medical care.  
Persons/Organizations Providing the Information  
Patient data and data from the WVU Chestnut Ridge /West Virginia University Hospi[INVESTIGATOR_600]/ WVU 
Medicine/ WVU  will be collected.  
Persons/Organizations Receiving the Information  
• This study will be conducted at the West Virginia University Chestnut Ridge Center 
(WVUCRC ), outpatient substance use disorder treatment and recovery program in north 
central Appalachia located at [ADDRESS_760083] Virginia, [ZIP_CODE].   
• Health care providers who provide services to you as part of this research study. 
• (Sponsor name, if applicable) and the people and companies that they use to oversee, manage, or conduct the research.  
• The members and staff of any institutional review board that oversees this research study.  
• The West Virginia University Office of Human Research Protection and the West Virginia 
University Office of Sponsored Programs.  
• If applicable, West Virginia University School of Nursing 
 
The Following Information Will Be Used  
Information from your existing medical records, and new information about you that is created or collected during this study, such as: demographic data and diagnosis data as it relates to your treatment for substance use disorder only.  
The Information is Being Disclosed for the Following Reasons  
• Publication of study results (without identifying you)  
• Other research purposes include reviewing the safety and feasibility of the aromatic 
intervention and developi[INVESTIGATOR_007] a better understanding of disease; improving the design of future clinical trials.  
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 [ADDRESS_760084]. Roger Carpenter at [EMAIL_11002] or Marian Reven at [EMAIL_11000]
.  
Refusal to participate or withdraw will not affect your future care or status at West Virginia University.  
In the event new information becomes available that may affect your willingness to participate in 
this study, this information will be given to you so that you can make an informed decision about whether or not to continue your participation.   
Contact [CONTACT_578381], concerns, or complaints about this research, you can contact [INVESTIGATOR_124]. Roger Carpenter (PI) at West Virginia University School of Nursing, [EMAIL_11002]
 or  Marian 
Reven (Co -I) West Virginia University School of Nursing, [EMAIL_11000] .  
If you are hurt from being in this research, you should contact [INVESTIGATOR_124]. Roger Carpenter at [PHONE_11994] Monday through Friday 9am to 5pm.   If injury occurs outside of business hours and is related to your participation in this research, please contact [CONTACT_578376] (Co -I) at [PHONE_11995].  
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 [ADDRESS_760085] the WVU Office of Human Research Protection (OHRP) at (304) 293 -7073 or by [CONTACT_25541] 
[EMAIL_10052] .   
 
Signatures and Authorization  
You have been given the opportunity to ask questions about the research (if applicable) and your authorization of HIPAA, and you have received answers concerning areas you did not understand.  Upon signing this form, you will receive a copy. 
 
Would you like us to contact [CONTACT_578382]?  Yes _________    No   ___________ 
If you agree to future contact, please fill in the information below. If you do not want future contact, your 
participation in this study will not be impacted.  Address:__________________________________________________________________________________________ Email:  ____________________________________________________ 
 
Participant Signature  
I willingly consent to participate in this research.  
 
Signature [CONTACT_578387]’s Legal Representative  
 
 
Printed Name   [CONTACT_578388].  The participant willingly 
agrees to be in the study. 
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 7  
Signature [CONTACT_578389]_______________________________ 
  
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 8 Appendix G (IRB Update allowing Stages one, two, three, and peer 
recovery recruitment) 
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 9  

PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 10 Appendix H (IRB approval to recruit online complete consent online)  
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 11  
 

PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 12 Appendix I (QIP Audit letter from IRB) 
PROTOCOL MANUAL: AROMATHERAPY & SUD 
 
   
 13  
